Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Search Results for: ESC Poster News

ESC Poster news: Long-term data with evolocumab in heterozygous FH

ESC Poster news: Long-term data with evolocumab in heterozygous FH

30th August 2016, Rome, Italy Evolocumab was effective and well tolerated in patients with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) treated for up to 48 weeks (1). Previously, the RUTHEFORD studies in heterozygous FH showed that evolocumab given for 12 weeks was effective in…

read more »
ESC Poster news: Consistent benefit with evolocumab in high and very high risk patients

ESC Poster news: Consistent benefit with evolocumab in high and very high risk patients

30th August 2016, Rome, Italy In a pooled analysis of more than 2500 patients, the LDL cholesterol lowering efficacy of evolocumab was consistent in both very high risk and high risk patients (1). The 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines categorise…

read more »
ESC Poster news: More reassurance on alirocumab safety at very low LDL cholesterol

ESC Poster news: More reassurance on alirocumab safety at very low LDL cholesterol

30th August 2016, Rome, Italy In an updated safety analysis for alirocumab treatment for up to 104 weeks, there was no evidence of any safety issues affecting neurological or neurocognitive function with alirocumab (1). Data were pooled from 14 Phase II and III trials, comprising…

read more »
ESC Poster news: Alirocumab effective in patients with multiple manifestations of cardiovascular disease

ESC Poster news: Alirocumab effective in patients with multiple manifestations of cardiovascular disease

30th August 2016, Rome, Italy Alirocumab, was effective and well tolerated in patients with multiple manifestations of cardiovascular disease receiving statins with or without other lipid lowering therapy, according to a post hoc analysis of the ODYSSEY trials (1). The investigators evaluated data from patients…

read more »
ESC Congress 2019 – News from Poster Sessions: Very low LDL cholesterol  in ODYSSEY OUTCOMES appears effective and safe

ESC Congress 2019 – News from Poster Sessions: Very low LDL cholesterol in ODYSSEY OUTCOMES appears effective and safe

Acute coronary syndrome (ACS) patients attaining very low LDL cholesterol levels in ODYSSEY OUTCOMES derived at least as much clinical benefit from alirocumab, despite blinded substitution with placebo. There was also no signal for any increase in neurocognitive events, haemorrhagic stroke or new-onset diabetes with…

read more »
ESC Congress 2019 – News from Poster Sessions: Real-world use of evolocumab in FH patients

ESC Congress 2019 – News from Poster Sessions: Real-world use of evolocumab in FH patients

In the largest cohort to date of patients with familial hypercholesterolaemia (FH, inherited high cholesterol) treated with a PCSK9 inhibitor in real-world practice, evolocumab was shown to be efficacious and well tolerated. This was a multicentre, observational study in 10 European countries. A total of…

read more »
News from ACC.22 – Long-term data from HAUSER-OLE in paediatric familial hypercholesterolaemia

News from ACC.22 – Long-term data from HAUSER-OLE in paediatric familial hypercholesterolaemia

Results from the HAUSER Open-Label Extension Study (HAUSER-OLE) (1) show that treatment with evolocumab was well tolerated, safe, and led to substantial reduction in LDL cholesterol in children with heterozygous familial hypercholesterolaemia (FH). As previously reported on PCSK9 Forum, HAUSER-RCT evaluated the efficacy and safety…

read more »
Lipid news from the poster sessions

Lipid news from the poster sessions

News from ESC Congress 2021 (Virtual) How common is statin intolerance? The latest findings from a worldwide systematic review and meta-analysis including over 4 million patients indicates a low prevalence of statin intolerance, especially when assessed objectively using recognized international criteria. In this report, the…

read more »
More news from the posters

More news from the posters

First data from OMERO: real-world experience with alirocumab OMERO is a prospective study evaluating the long-term effectiveness, tolerability, and safety of alirocumab (on top of standard lipid lowering therapy) in real-world practice in Italy.  This interim report provides data from 352 (out of 800) patients…

read more »
More poster news: Patient-reported barriers to use of PCSK9 inhibitors

More poster news: Patient-reported barriers to use of PCSK9 inhibitors

Results from this web-based US survey show that cost was the main reason given by patients for low initial and ongoing use of PCSK9 inhibitors. This survey was completed by 769 patients who signed up for a pharmaceutical company-sponsored patient support program after prescription for…

read more »
AT-TARGET-IT: Real world data show high adherence to PCSK9 inhibitors

AT-TARGET-IT: Real world data show high adherence to PCSK9 inhibitors

Real world data from the AT-TARGET-IT multicentre, observational registry in Italy have shown substantial reductions in LDL-cholesterol (LDL-C) and high levels of LDL-C target achievement with PCSK9 inhibitors (PCSK9i), leading to very high adherence and therapy persistence.1 Recently reported results from 798 patients enrolled in…

read more »